CEVI Stock Overview
Develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
CellaVision AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 211.50 |
| 52 Week High | SEK 302.00 |
| 52 Week Low | SEK 164.00 |
| Beta | 1.23 |
| 11 Month Change | -24.19% |
| 3 Month Change | -16.73% |
| 1 Year Change | 22.82% |
| 33 Year Change | -40.95% |
| 5 Year Change | -31.44% |
| Change since IPO | 1,255.77% |
Recent News & Updates
Does CellaVision (STO:CEVI) Have A Healthy Balance Sheet?
Nov 20
CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oct 27Recent updates
Does CellaVision (STO:CEVI) Have A Healthy Balance Sheet?
Nov 20CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oct 27CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Jul 24Is CellaVision (STO:CEVI) A Risky Investment?
Jun 07Does CellaVision (STO:CEVI) Deserve A Spot On Your Watchlist?
May 22CellaVision (STO:CEVI) Is Due To Pay A Dividend Of SEK2.25
Apr 13CellaVision AB (publ)'s (STO:CEVI) Intrinsic Value Is Potentially 46% Above Its Share Price
Apr 09CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Mar 28CellaVision's (STO:CEVI) Dividend Will Be SEK2.25
Mar 14CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Feb 29After Leaping 28% CellaVision AB (publ) (STO:CEVI) Shares Are Not Flying Under The Radar
Feb 16CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Feb 12Earnings Beat: CellaVision AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 10CellaVision's (STO:CEVI) Returns On Capital Not Reflecting Well On The Business
Dec 13Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?
Sep 14Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)
Aug 22CellaVision (STO:CEVI) Is Reinvesting At Lower Rates Of Return
Jun 17CellaVision's (STO:CEVI) Upcoming Dividend Will Be Larger Than Last Year's
May 07Estimating The Fair Value Of CellaVision AB (publ) (STO:CEVI)
Apr 19CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.25
Apr 05CellaVision (STO:CEVI) Is Paying Out A Larger Dividend Than Last Year
Mar 04CellaVision AB (publ) (STO:CEVI) Analysts Are More Bearish Than They Used To Be
Feb 11Is CellaVision (STO:CEVI) A Risky Investment?
Jan 13Is CellaVision AB (publ) (STO:CEVI) Potentially Undervalued?
Dec 13CellaVision (STO:CEVI) Seems To Use Debt Rather Sparingly
Sep 23CellaVision (STO:CEVI) May Have Issues Allocating Its Capital
Aug 16Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)
Aug 02We Ran A Stock Scan For Earnings Growth And CellaVision (STO:CEVI) Passed With Ease
Jun 27What Is CellaVision AB (publ)'s (STO:CEVI) Share Price Doing?
May 31Shareholder Returns
| CEVI | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -11.5% | -4.1% | -2.1% |
| 1Y | 22.8% | -9.7% | 10.8% |
Return vs Industry: CEVI exceeded the Swedish Medical Equipment industry which returned -4.1% over the past year.
Return vs Market: CEVI exceeded the Swedish Market which returned 12.5% over the past year.
Price Volatility
| CEVI volatility | |
|---|---|
| CEVI Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: CEVI has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: CEVI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 228 | Simon Ostergaard | www.cellavision.com |
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process.
CellaVision AB (publ) Fundamentals Summary
| CEVI fundamental statistics | |
|---|---|
| Market cap | SEK 5.04b |
| Earnings (TTM) | SEK 150.21m |
| Revenue (TTM) | SEK 737.16m |
33.6x
P/E Ratio6.8x
P/S RatioIs CEVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CEVI income statement (TTM) | |
|---|---|
| Revenue | SEK 737.16m |
| Cost of Revenue | SEK 243.34m |
| Gross Profit | SEK 493.83m |
| Other Expenses | SEK 343.61m |
| Earnings | SEK 150.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 6.30 |
| Gross Margin | 66.99% |
| Net Profit Margin | 20.38% |
| Debt/Equity Ratio | 4.6% |
How did CEVI perform over the long term?
See historical performance and comparison